Skip to content

Clinical trials

Phase 2/3 trials in China with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Phase: Phase 2/3 Status: Unknown status Country / region: China Clear all

316 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20031
20041
20051
20061
20072
20084
20094
201015
20116
201219
201323
201424
201522
201619
201724
201833
201923
202024
202127
202225
202311
20245

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status316

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Nanfang Hospital, Southern Medical University24
Fudan University14
Peking Union Medical College Hospital13
Sun Yat-sen University12
Fujian Medical University11
Tianjin Medical University Cancer Institute and Hospital8
Ruijin Hospital6
Second Affiliated Hospital, Zhejiang University, School of Medicine6
Capital Medical University5
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Breast Neoplasms14
Carcinoma, Hepatocellular14
Stomach Neoplasms10
Leukemia, Myeloid, Acute9
Carcinoma, Non-Small-Cell Lung8
Ischemic Stroke7
Colorectal Neoplasms6
Precursor Cell Lymphoblastic Leukemia-Lymphoma6
Arthritis, Rheumatoid5
Esophageal Neoplasms5

Trials

Showing 1 to 25 of 316. Each trial links to its page on Pharma Observatory.

216 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.